Verastem Q3 2024 Earnings Report

Verastem EPS Results

• Actual EPS: -$0.60
• Consensus EPS: -$0.71
• Beat/Miss: Beat by +$0.11
• One Year Ago EPS: N/A

Verastem Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Verastem Announcement Details

• Quarter: Q3 2024
• Date: 11/6/2024
• Time: After Market Closes
• Conference Call Date: Wednesday, November 6, 2024
• Conference Call Time: 4:00PM ET

Verastem (NASDAQ:VSTM) Oncology, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapies that target cancer stemness and resistance pathways. Established in 2010 and headquartered in Needham, Massachusetts, Verastem Oncology applies a precision-medicine approach to identify key signaling nodes responsible for tumor growth and relapse, with an emphasis on hematologic malignancies and solid tumors. The company’s research platform integrates insights into complex signaling networks to advance novel compounds from early discovery through clinical proof of concept.

The company’s lead marketed product is COPIKTRA (duvelisib), an oral inhibitor of PI3K-delta and PI3K-gamma, which received U.S. Food and Drug Administration approval in 2018 for the treatment of relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma and follicular lymphoma. In parallel, Verastem Oncology has built a differentiated pipeline of targeted therapies, including selective Rho/MRTF pathway inhibitors and focal adhesion kinase (FAK) inhibitors, which are being evaluated in various solid tumor and blood cancer settings. Ongoing clinical trials are designed to explore monotherapy activity as well as combination regimens that may overcome resistance and improve patient outcomes.

Verastem Oncology conducts its clinical and translational research activities primarily in the United States, with strategic partnerships and investigator-initiated studies extending into Europe. The company collaborates with academic institutions and industry partners to accelerate the development of its pipeline assets. Verastem Oncology’s leadership team comprises experienced drug developers and oncology specialists who are committed to advancing novel therapies that address unmet medical needs in cancer treatment.